GSP Crop Science Q1 FY27: Revenue Stable at ₹386 Cr, PAT Up 16% to ₹26.4 Cr

GSP Crop Science Limited announced the transcript of its post-results conference call for the quarter ended June 30, 2026, held on August 12, 2026. The company reported stable revenue of ₹386 crore for Q1 FY27, a slight increase from ₹377 crore in the same quarter last year, driven by strong domestic business momentum. This was partly offset by temporary raw material constraints in the international segment.

The company highlighted its focus on patented products and differentiated offerings, with domestic B2C contributing around 45%, domestic B2B around 45%, and exports around 10% of the revenue in Q1 FY27. Export business is expected to gain momentum in the second half of the financial year.

Gross margins improved due to a shift towards specialty and differentiated products. However, employee costs increased due to annual increments and a slight rise in headcount, alongside higher power and fuel costs. EBITDA stood at 11%. Other income saw a significant boost from the sale of land. Depreciation increased due to the capitalization of the backward integration plant at Dahej, Saykha. Interest costs decreased due to the repayment of loans using IPO funds.

Profit After Tax (PAT) increased by approximately 16% to ₹26.4 crore in the first quarter. ICRA has upgraded the company's rating from A to A+ stable, citing loan repayment from IPO proceeds and consistent good performance.

Management discussed the strategy to double the patented product share in the next 2-3 years and expand into new segments like herbicides and potato-specific products. The company aims to scale its domestic market share from the current 3-3.5% to 7-8%. The R&D pipeline includes 1-2 new technical products and 2-3 patented formulations annually for the next 4-5 years. Key growth markets identified are Latin America, Brazil, and the USA, with plans to expand into Africa and other Asian countries.

Capacity utilization for technical facilities is at 70-75%, with room for growth and product swapping for higher-value items. Formulation plant utilization is around 25-30%, which is typical as these plants are designed for peak season demand and can also be outsourced. The company anticipates growing at approximately 15% annually, with EBITDA and PAT margins expected to improve due to a better product mix and reduced interest costs. Mid-term targets include growing EBITDA by 13-14% over the next 2-3 years.